ARIAD Pharmaceuticals (ARIA) :The total money flow, which is calculated as the dollar value of composite uptick minus downtick trades was negative ($15.84 million) and the uptick to downtick ratio was 0.37. The transaction value on upticks was $9.45 million and on downticks, the transaction value was $25.28 million. In block trades, the transaction value of inflow done during uptick was $1.11 million. The transaction value of block trades during downticks was $16.75 million. The uptick to downtick block trade ratio was 0.07. The money flow was negative ($15.65 million), indicating the traders were booking profit on the price strength. ARIAD Pharmaceuticals (ARIA) rose $0.19 at $14.14, during intraday Wednesday , a rise of 1.36% over the previous days close.
Shares of Ariad Pharmaceuticals Inc. rose by 5.44% in the last five trading days and 38.49% for the last 4 weeks. Ariad Pharmaceuticals Inc. is up 89.54% in the last 3-month period. Year-to-Date the stock performance stands at 126.24%.
ARIAD Pharmaceuticals (ARIA) : Zacks Investment Research ranks ARIAD Pharmaceuticals (ARIA) as 1, which is a Strong Buy recommendation. 4 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 more believe that the stock has more downside risks, hence they propose a Strong Sell. The average broker rating of 5 research analysts is 1.8, which indicates as a Buy.
ARIAD Pharmaceuticals (NASDAQ:ARIA): The stock opened at $14.15 and touched an intraday high of $14.26 on Wednesday. During the day, the stock corrected to an intraday low of $13.83, however, the bulls stepped in and pushed the price higher to close in the green at $14.14 with a gain of 1.36% for the day. The total traded volume for the day was 5,988,867. The stock had closed at $13.95 in the previous trading session.
ARIAD Pharmaceuticals, Inc. is a global oncology company. The Company is engaged in the discovery, development and commercialization of small molecule drug indicated for the treatment of cancer. The Companys product pipeline includes Iclusig (ponatinib), brigatinib (AP26113), AP32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI), which is approved in the United States, Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). AP32788, is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).